During an interview with Radio Television Hong Kong, Chief Executive John Lee Ka-chiu stated that the long-term goal of the authorities is to have their own drug regulatory agency capable of approving medications and medical devices. To achieve this goal, an organizing office must be established to prepare, including joining international organizations and strengthening clinical research.

John Lee Ka-chiu mentioned that Hong Kong and the mainland can jointly leverage advantages in clinical trials, including utilizing mainland data, such as the patient database of 1.4 billion people or nearly 80 million people in the Greater Bay Area. When top-tier clinical trials can be conducted, it will attract pharmaceutical companies to Hong Kong, increasing competitiveness and business opportunities.